Summit Therapeutics plc - Company & Market Research Reports

Summit Therapeutics is a biopharmaceutical company focussed on the development of novel medicines to treat the fatal muscle wasting disease Duchenne muscular dystrophy and infections caused by the bacteria C. difficile. The company is developing Ezutromid, an utrophin modulator product candidate that is in Phase II clinical trials used for to treat Duchenne muscular dystrophy disease. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.


Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022 - Product Thumbnail Image

Global Duchenne Muscular Dystrophy Therapeutics Market By Drug, By Therapeutic Approach Clinical Trial Assessment & Pipeline Analysis Outlook 2022

  • Report
  • 100 Pages
From
Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017

  • Report
  • 79 Pages
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • 35 Pages
From
Duchenne Muscular Dystrophy - Pipeline Review, H1 2018 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H1 2018

  • Report
  • 305 Pages
From
Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026 - Product Thumbnail Image

Duchenne Muscular Dystrophy (DMD): Competitive Landscape to 2026

  • Report
  • 49 Pages
From
OpportunityAnalyzer: Clostridium difficile Infections - Opportunity Analysis and Forecasts to 2026 - Product Thumbnail Image

OpportunityAnalyzer: Clostridium difficile Infections - Opportunity Analysis and Forecasts to 2026

  • Drug Pipelines
  • 281 Pages
From
2018 Diarrhea Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Diarrhea Drug Development- Pipeline Analysis Report

  • Report
  • 70 Pages
From
2018 Trigeminal Neuralgia Drug Development- Pipeline Analysis Report - Product Thumbnail Image

2018 Trigeminal Neuralgia Drug Development- Pipeline Analysis Report

  • Report
  • 35 Pages
From
Global Clostridium Difficile Treatment Market 2017-2021 - Product Thumbnail Image

Global Clostridium Difficile Treatment Market 2017-2021

  • Report
  • 70 Pages
From
Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018 - Product Thumbnail Image

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline Review, H1 2018

  • Report
  • 202 Pages
From
Clostridium difficile Infections - Pipeline Review, H1 2017 - Product Thumbnail Image

Clostridium difficile Infections - Pipeline Review, H1 2017

  • Report
  • 188 Pages
From
Q4 2017 Earnings Call - Summit Therapeutics Plc, - Earnings Transcript - Product Thumbnail Image

Q4 2017 Earnings Call - Summit Therapeutics Plc, - Earnings Transcript

  • Earnings Transcript
Summit Therapeutics plc and Sarepta Therapeutics Inc Collaboration Agreement Call - Sarepta Therapeutics, Inc., - Earnings Transcript - Product Thumbnail Image

Summit Therapeutics plc and Sarepta Therapeutics Inc Collaboration Agreement Call - Sarepta Therapeutics, Inc., - Earnings Transcript

  • Earnings Transcript
Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Duchenne Muscular Dystrophy Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 166 Pages
From
Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017 - Product Thumbnail Image

Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2017

  • Clinical Trials
  • 183 Pages
From
Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026  - Product Thumbnail Image

Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming Opportunities, 2016-2026

  • Report
  • 266 Pages
From
Diarrhea - Pipeline Review, H1 2018 - Product Thumbnail Image

Diarrhea - Pipeline Review, H1 2018

  • Report
  • 154 Pages
From
Diarrhea - Pipeline Review, H2 2017 - Product Thumbnail Image

Diarrhea - Pipeline Review, H2 2017

  • Report
  • 146 Pages
From
Tauopathies - Pipeline Review, H2 2015 - Product Thumbnail Image

Tauopathies - Pipeline Review, H2 2015

  • Report
  • 54 Pages
From
Tauopathies - Pipeline Review, H1 2015 - Product Thumbnail Image

Tauopathies - Pipeline Review, H1 2015

  • Report
  • 54 Pages
From
Loading Indicator
adroll